Close

Presentation

User experience improvement in manual self-injection of viscous solutions with 8mm ultra-thin wall needle syringes (BD Neopak™ XtraFlow™)
Event Type
Poster Presentation
TimeThursday, April 152:00pm - 3:00pm EDT
LocationMedical and Drug Delivery Devices
DescriptionChronic diseases are on the rise worldwide and require regular administration of drug therapies to relieve the patients from their symptoms. Biologics, and more specifically Monoclonal antibodies (mAbs), are becoming dominant in the biopharmaceutical pipeline thanks to their success in treating chronic conditions. The chronic condition injectable market is growing at a high pace with a strong market conversion to Pre-fillable Syringes (PFS).
Great progress and efforts were made in offering drug delivery systems for chronic diseases. However, several market unmet needs persist and should be considered when developing new manual drug delivery solutions. For manual injection options with naked PFS with or without safety device, risks of intramuscular injection, injection-related anxiety/ pain perception, effort and time required to perform the injection have been identified as key unmet needs. Offering a way to manually deliver more viscous and higher volume drugs without compromising the patient’s experience and safety (reduction of unwanted intramuscular injection and needle-related anxiety/pain) is even more relevant today as many pipeline biologic drugs are being formulated with higher viscosity and/or higher volume to achieve less frequent injection. Improving chronic disease patient manual injection experience could also participate to enhance treatment adherence. Importantly, as autoinjector solutions are expanding, higher viscosity/volume drugs are further constraining the device development process to ensure safe injections in the subcutaneous layer.
8mm needles will improve the risk profile associated to subcutaneous injections and allow easier or quicker injections than with standard 12.7mm (1/2”) needles. When combined with ultra-thin wall technology, these new needles will allow injecting higher viscosities/volumes without compromising the injection experience, manually or when using automatic drug delivery solutions. BD Medical - Pharmaceutical Systems (BDM-PS) present through mathematical models and Human factors data how shorter 8mm and ultra-thin wall needle solutions can address the chronic market unmet needs previously described.